Abstract 1284P
Background
Lung cancer (LC) is the leading cause of cancer-related death worldwide, and up to five times more likely to occur in smokers with chronic obstructive pulmonary disease (COPD) than those with normal lung function. In this study, we investigated the overlap between patients registered with COPD and patients examined on suspicion of LC over a 10-year period in the Region of Southern Denmark.
Methods
The National Registry of COPD and the Danish LC Registry delivered data on patients with COPD and LC respectively. The cohort referred for LC diagnostics was defined by assigned classification codes provided from the Health Care Classification System.
Results
During the study period, 25,647 patients were registered with COPD during hospitalizations, or from outpatient clinics. Among these, 5.030 patients (20%) were referred to LC diagnostics, and 1,551 were diagnosed with LC. This corresponds to a LC incidence of 6% among all patients with COPD, and 31% among COPD patients referred for LC diagnostics. COPD patients referred for LC diagnostics were generally more affected by COPD compared to the group of not referred for LC diagnostics. Referred patients collected more COPD related medication (6 of 7 medicaments), performed worse in terms of lung function (FEV1% 48% vs. 50%), suffered from a higher grade of dyspnea (71% vs. 57% MRC 3-5) and experiences a higher rate of exacerbations (42% vs. 31% with 2-3 exacerbations) compared to COPD patients not referred to LC diagnostics (p<0.05 for all). Among all patients who underwent LC diagnostics, COPD patients displayed a higher prevalence of LC compared to the non-COPD patients (31% vs. 29%, p<0.005). LC patients with COPD were more likely to be stage I-II compared to the non-COPD LC population (39% vs. 24%, p<0.05).
Conclusions
This study reveals a substantial overlap between patients with COPD and patients undergoing LC diagnostics (20%). It suggests that patients more affected by COPD are more likely to undergo LC diagnostics, and LC patients with COPD are more likely to be diagnosed in early stages. It underlines the overrepresentation of LC patients among patients with COPD, and emphasizes the need to address these patients specifically once initiating a screening program.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Margrethe Bang Henriksen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
478P - Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study
Presenter: Antonella Palazzo
Session: Poster session 04
479P - Radiomics to predict HER2 status in breast cancer brain metastases
Presenter: Gaia Griguolo
Session: Poster session 04
480P - Prognostic significance of somatic DNA gene rearrangement and structural atypia in metastatic breast cancer
Presenter: Hiroshi Tada
Session: Poster session 04
481P - Second generation oral selective estrogen receptor degraders (SERDs) in breast cancer: A systematic review and meta-analysis of clinical trials
Presenter: Maysa Silveira Vilbert
Session: Poster session 04
482P - Precision imaging with human epidermal growth factor receptor 2-positron emission tomography (HER2-PET) for refined treatment selection in patients with HER2-low breast cancer
Presenter: Siri af Burén
Session: Poster session 04
483P - Prognostic value of androgen receptor expression in patients with advanced triple-negative metastatic breast cancer treated with sacituzumab govitecan: A French multicentre retrospective study
Presenter: Monica Arnedos
Session: Poster session 04
484P - Multi-platform characterization of HER2 expression in triple-negative breast cancer
Presenter: Ana C Garrido-Castro
Session: Poster session 04
485P - A novel approach to identify subpopulation of CTCs with metastatic potential using sc-RNA-seq
Presenter: Evgeniya Grigoryeva
Session: Poster session 04
486P - The influence of NF1 germline and somatic mutations on breast cancer patient survival
Presenter: Roope Kallionpää
Session: Poster session 04
487P - Induction of an inflammatory tumor microenvironment with oncolytic virus CF33-hNIS-antiPD-L1 intratumoral injection in patients with metastatic triple-negative breast cancer (mTNBC)
Presenter: Jamie Rand
Session: Poster session 04